Drug-induced valvular heart disease

Heart

Volumn 99, Issue 1, 2013, Pages 7-12

  Cosyns, Bernard ^a   Droogmans, Steven ^a   Rosenhek, Raphael ^b   Lancellotti, Patrizio ^c  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BENFLUOREX; BROMOCRIPTINE; CABERGOLINE; CYPROHEPTADINE; ERGOTAMINE; FENFLURAMINE; GUANFACINE; METHYSERGIDE; PERGOLIDE; PHENTERMINE; QUINIDINE; SEROTONIN 2B RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

AORTA VALVE DISEASE; AORTA VALVE REGURGITATION; CALCIFICATION; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; DRUG INDUCED VALVULAR HEART DISEASE; ECHOCARDIOGRAPHY; ENDOCARDITIS; HISTOPATHOLOGY; HUMAN; HYPERPROLACTINEMIA; LIBMAN SACKS ENDOCARDITIS; LOW DRUG DOSE; MALARIA; MIGRAINE; MITRAL VALVE DISEASE; MITRAL VALVE REGURGITATION; NONHUMAN; OBESITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; RHEUMATIC HEART DISEASE; TREATMENT DURATION; TRICUSPID VALVE DISEASE; VALVULAR HEART DISEASE;

DOPAMINE AGONISTS; ERGOLINES; HEART VALVE DISEASES; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PARKINSON DISEASE; PREVALENCE; SEROTONIN AGENTS; WORLD HEALTH;

EID: 84871270187     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302239     Document Type: Review

References (35)

1. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8. (Pubitemid 27360757)
2. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-83. (Pubitemid 38481842)
3. Droogmans S, Cosyns B, D 'Haenen H, et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 2007;100:1442-5. (Pubitemid 47576024)
4. Dahl CF, Allen MR, Urie PM, et al. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008;6:34.
5. Greffe G, Chalabreysse L, Mouly-Bertin C, et al. Valvular heart disease associated with fenfluramine detected 7 years after discontinuation of treatment. Ann Thorac Surg 2007;83:1541-3. (Pubitemid 46440768)
6. Droogmans S, Franken PR, Garbar C, et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 2007;28:2156-62. (Pubitemid 47517444)
7. Elangbam CS. Drug-induced valvulopathy: an update. Toxicol Pathol 2010;38:837-48.
8. Droogmans S, Kerkhove D, Cosyns B, et al. Role of echocardiography in toxic heart valvulopathy. Eur J Echocardiogr 2009;10:467-76.
9. Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703-9. (Pubitemid 30196210)
10. Weissman NJ, Tighe JF Jr, Gottdiener JS, et al. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfl uramine Study Group. N Engl J Med 1998;339:725-32. (Pubitemid 28417355)
11. Sachdev M, Miller WC, Ryan T, et al. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 2002;144:1065-73. (Pubitemid 36026921)
12. Hopkins PN, Polukoff GI. Risk of valvular heart disease associated with use of fenfluramine. BMC Cardiovasc Disord 2003;3:5.
13. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46. (Pubitemid 46041752)
14. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-9. (Pubitemid 47243713)
15. Corvol JC, Anzouan-Kacou JB, Fauveau E, et al. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis. Arch Neurol 2007;64:1721-6. (Pubitemid 350254933)
16. Simonis G, Fuhrmann JT, Strasser RH. Meta-analysis of heart valve abnormalities in Parkinson' s disease patients treated with dopamine agonists. Mov Disord 2007;22:1936-42. (Pubitemid 350134208)
17. Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008;93:3777-84.
18. Kars M, Pereira AM, Bax JJ, et al. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 2008;159:363-7.
19. Rasmussen VG, Ostergaard K, Dupont E, et al. The risk of valvular regurgitation in patients with Parkinson 's disease treated with dopamine receptor agonists. Mov Disord 2011;26:801-6.
20. Weill A, Paita M, Tuppin P, et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010;19:1256-62.
21. Boudes A, Lavoute C, Avierinos JF, et al . Valvular heart disease associated with benfluorex therapy: high prevalence in patients with unexplained restrictive valvular heart disease. Eur J Echocardiogr 2011;12:688-95.
22. Gu H, Luck S, Carroll PV, et al. Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Clin Endocrinol (Oxf) 2011;74:608-10.
23. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT (2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81. (Pubitemid 30033262)
24. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-41.
25. Hutcheson JD, Setola V, Roth BL, et al. Serotonin receptors and heart valve disease-it was meant 2B. Pharmacol Ther 2011;132:146-57.
26. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9.
27. Droogmans S, Roosens B, Cosyns B, et al. Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study. Am J Physiol Heart Circ Physiol 2009;296:H1940-8.
28. Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
29. Lancellotti P, Marwick T, Pierard LA. How to manage ischaemic mitral regurgitation. Heart 2008;94:1497-502.
30. Hojnik M, George J, Ziporen L, et al . Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996;93:1579-87. (Pubitemid 26115423)
31. Huang XP, Setola V, Yadav PN, et al. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol 2009;76:710-22.
32. Droogmans S, Roosens B, Cosyns B, et al. Dose dependency and reversibility of serotonin-induced valvular heart disease in rats. Cardiovasc Toxicol 2009;9:134-41.
33. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38. (Pubitemid 46041751)
34. Worthington A, Thomas L. Valvular heart disease associated with taking low-dose pergolide for restless legs syndrome. Eur J Echocardiogr 2008;9:828-30.
35. Shively BK, Roldan CA, Gill EA, et al. Prevalence and determinants of valvulopathy in patients treated with dexfen fluramine. Circulation 1999;100:2161-7.